深研生物 is an upstream core supplier in the cell and gene therapy (CGT) sector, focused on自主研发 (in‑house R&D) of core technologies and equipment. The company positions itself to help China’s CGT industry reduce costs and improve efficiency. It announced an oversubscribed B+ financing round totaling more than RMB 300 million. The round was led by 越秀产业基金 (Yuexiu Industry Fund) with participation from 达晨财智, 粤科金融, 天士力资本, 亚商资本, 清水湾二期 and others; existing investor 斯道资本 and an unnamed international industrial group also continued to follow on. 凯乘资本 served as the exclusive financial adviser for this financing. The financing was reported by IT桔子 and covered in DoNews. Eurekabio is a China-based manufacturing supplies platform serving the cell and gene therapy (CGT) industry. Founded in 2014, the company provides comprehensive solutions through interdisciplinary expertise and technological innovation. Its core offerings include CGT manufacturing equipment and consumables and the EuLV platform, a large-scale viral vector production technology based on a stable cell line. Eurekabio plans to use the recent financing to expand its pipeline and commercial footprint for CGT manufacturing equipment and consumables. The company will also strengthen R&D of the EuLV platform to bring more core technologies and products that reduce cost and improve efficiency for the CGT industry.

Total raised

$40M

Funding rounds

2

Latest round

Series B

Latest activity

Mar 2024